Payment overview · 2025
General Payments
$2,598.68
141 reported records · 30 companies
Healthcare provider profile · identity verified
Michael Gene Mcpherson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LUBBOCK, TX · NPI 1053322016
Verified facts
What the public records show
CMS Open Payments records show Michael Gene Mcpherson, MD received $2,598.68 in general payments during 2025 across 141 reported records.
ABBVIE INC. accounted for 13.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Linzess, Lokelma, Mounjaro, Nuedexta, Ozempic, Rexulti, Trelegy Ellipta, Tymlos, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 541 claims for Eliquis by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Tymlos by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Soliqua 100-33 by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $338.45 | 13.0% | 19 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $314.35 | 12.1% | 18 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $241.98 | 9.3% | 21 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $206.05 | 7.9% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $197.14 | 7.6% | 13 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $130.09 | 5.0% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $115.06 | 4.4% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $99.94 | 3.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $90.94 | 3.5% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $88.75 | 3.4% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $78.87 | 3.0% | 3 | 2025 |
| Krystal Biotech Inc | Unresolved — no canonical attribution shown | $74.08 | 2.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $61.95 | 2.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.07 | 2.3% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $58.07 | 2.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.06 | 2.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.29 | 2.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.28 | 2.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.88 | 1.6% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $39.85 | 1.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.74 | 1.4% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $27.00 | 1.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $23.49 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.69 | 0.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.46 | 0.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.99 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.72 | 0.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.56 | 0.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.17 | 0.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.71 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,556.18 | 140 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $288.24 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $246.84 | 15 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $222.84 | 12 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $184.81 | 10 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $130.09 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $125.10 | 8 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $125.10 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $124.05 | 14 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $121.69 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $116.88 | 13 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $115.06 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $104.83 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $88.75 | 4 | 2025 |
Source payment records
|
|||||
| FLULAVAL QUADRIVALENT Normalized: flulaval quadrivalent |
Biological | GlaxoSmithKline, LLC. | $80.44 | 5 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $78.87 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.45 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $75.45 | 4 | 2025 |
Source payment records
|
|||||
| VYJUVEK Normalized: vyjuvek |
Drug | Krystal Biotech Inc | $74.08 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $67.51 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $61.95 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $60.07 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $58.07 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $58.06 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.32 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.28 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.28 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.88 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $10.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $10.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 119 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 188 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 165 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 45 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 321 | exact normalized | Medicare Part D |
| NUEDEXTA nuedexta |
2025 | Nuedexta | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 132 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
83 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
119 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
132 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
321 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
153 | 34 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 36 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
541 | 100 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
188 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1269 | 294 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1056 | 301 |
| Amlodipine Besylate | Amlodipine Besylate | 887 | 226 |
| Gabapentin | Gabapentin | 751 | 217 |
| Lisinopril | Lisinopril | 737 | 190 |
| Pantoprazole Sodium | Pantoprazole Sodium | 663 | 203 |
| Furosemide | Furosemide | 652 | 146 |
| Eliquis | Apixaban | 541 | 100 |
| Potassium Chloride | Potassium Chloride | 525 | 152 |
| Losartan Potassium | Losartan Potassium | 524 | 146 |
| Tamsulosin Hcl | Tamsulosin Hcl | 492 | 123 |
| Metformin Hcl | Metformin Hcl | 434 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 419 | 123 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 406 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 355 | 94 |
| Duloxetine Hcl | Duloxetine Hcl | 349 | 88 |
| Mounjaro | Tirzepatide | 321 | 58 |
| Donepezil Hcl | Donepezil Hcl | 305 | 59 |
| Omeprazole | Omeprazole | 305 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 284 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 274 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 265 | 57 |
| Buspirone Hcl | Buspirone Hcl | 264 | 76 |
| Trazodone Hcl | Trazodone Hcl | 254 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 85 |
| Sertraline Hcl | Sertraline Hcl | 232 | 61 |
| Meloxicam | Meloxicam | 223 | 73 |
| Montelukast Sodium | Montelukast Sodium | 223 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 219 | 77 |
| Carvedilol | Carvedilol | 218 | 68 |
| Tramadol Hcl | Tramadol Hcl | 214 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 52 |
| Simvastatin | Simvastatin | 203 | 48 |
| Allopurinol | Allopurinol | 188 | 60 |
| Gemtesa | Vibegron | 188 | 12 |
| Memantine Hcl | Memantine Hcl | 185 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 72 |
| Hydralazine Hcl | Hydralazine Hcl | 179 | 47 |
| Levetiracetam | Levetiracetam | 174 | 30 |
| Glimepiride | Glimepiride | 171 | 50 |
| Jardiance | Empagliflozin | 165 | 54 |
| Ozempic | Semaglutide | 161 | 36 |
| Mirtazapine | Mirtazapine | 159 | 50 |
| Finasteride | Finasteride | 157 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 154 | 44 |
| Trulicity | Dulaglutide | 153 | 34 |
| Alendronate Sodium | Alendronate Sodium | 147 | 38 |
| Gentamicin Sulfate | Gentamicin Sulfate | 139 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 135 | 49 |
| Famotidine | Famotidine | 134 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 132 | 30 |
| Methocarbamol | Methocarbamol | 129 | 36 |
| Nifedipine Er | Nifedipine | 128 | 39 |
| Januvia | Sitagliptin Phosphate | 126 | 12 |
| Farxiga | Dapagliflozin Propanediol | 119 | 28 |
| Celecoxib | Celecoxib | 110 | 40 |
| Paroxetine Hcl | Paroxetine Hcl | 110 | 23 |
| Atenolol | Atenolol | 103 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 29 |
| Divalproex Sodium | Divalproex Sodium | 102 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 102 | 66 |
| Spironolactone | Spironolactone | 101 | 31 |
| Metformin Hcl Er | Metformin Hcl | 98 | 27 |
| Xarelto | Rivaroxaban | 95 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 88 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 86 | 32 |
| Myrbetriq | Mirabegron | 83 | 24 |
| Ezetimibe | Ezetimibe | 82 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 80 | 27 |
| Baclofen | Baclofen | 80 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 26 |
| Risperidone | Risperidone | 72 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 28 |
| Prednisone | Prednisone | 70 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 68 | 14 |
| Fentanyl | Fentanyl | 68 | suppressed |
| Glipizide Er | Glipizide | 65 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 45 |
| Tresiba Flextouch U-200 | Insulin Degludec | 65 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 64 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 38 |
| Clonidine Hcl | Clonidine Hcl | 60 | 23 |
| Lactulose | Lactulose | 60 | 16 |
| Midodrine Hcl | Midodrine Hcl | 60 | 25 |
| Sodium Chloride | 0.9 % Sodium Chloride | 60 | 32 |
| Levofloxacin | Levofloxacin | 59 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 40 |
| Alprazolam | Alprazolam | 56 | 19 |
| Benztropine Mesylate | Benztropine Mesylate | 56 | suppressed |
| Glipizide | Glipizide | 55 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 17 |
| Azelastine Hcl | Azelastine Hcl | 54 | 24 |
| Bupropion Xl | Bupropion Hcl | 54 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | 15 |
| Lamotrigine | Lamotrigine | 54 | 11 |
| Latanoprost | Latanoprost | 53 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 53 | suppressed |
| Nystatin | Nystatin | 51 | 29 |
| Olanzapine | Olanzapine | 51 | 16 |
| Synthroid | Levothyroxine Sodium | 51 | 15 |
| Estradiol | Estradiol | 49 | 20 |
| Ibuprofen | Ibuprofen | 49 | 19 |
| Sucralfate | Sucralfate | 49 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Topiramate | Topiramate | 46 | suppressed |
| Linzess | Linaclotide | 45 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | 23 |
| Doxepin Hcl | Doxepin Hcl | 44 | 12 |
| Ondansetron Odt | Ondansetron | 44 | 31 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | 17 |
| Lovastatin | Lovastatin | 43 | 14 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Pregabalin | Pregabalin | 42 | 15 |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Torsemide | Torsemide | 42 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 11 |
| Brilinta | Ticagrelor | 41 | suppressed |
| Irbesartan | Irbesartan | 41 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 19 |
| Raloxifene Hcl | Raloxifene Hcl | 39 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 34 | 12 |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | 12 |
| Valsartan | Valsartan | 34 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Daptomycin | Daptomycin | 31 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | 12 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Insulin Lispro | Insulin Lispro | 30 | 15 |
| Primidone | Primidone | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 21 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Ertapenem | Ertapenem Sodium | 29 | suppressed |
| Nystop | Nystatin | 29 | 19 |
| Diazepam | Diazepam | 28 | 11 |
| Humalog | Insulin Lispro | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Lubiprostone | Lubiprostone | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | 15 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | 13 |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 24 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 22 | 16 |
| Cefdinir | Cefdinir | 21 | 15 |
| Humulin R | Insulin Regular, Human | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | 16 |
| Cefepime-Dextrose | Cefepime Hcl In Dextrose 5 % | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Nabumetone | Nabumetone | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 17 |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 17 |
| Phenytoin | Phenytoin | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 12 |
| Fluconazole | Fluconazole | 17 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | 14 |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Tymlos | Abaloparatide | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fluorometholone | Fluorometholone | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Permethrin | Permethrin | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | 11 |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,598.68 · 141 records | ABBVIE INC. | AFREZZA, AIRSUPRA, AREXVY, AUSTEDO XR, BEXSERO, CAPLYTA, CREON, Cologuard Collection Kit, FARXIGA, FLULAVAL QUADRIVALENT, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, JOURNAVX, Kerendia, LEQVIO, LINZESS, LOKELMA, Leqembi, MOUNJARO, NEXLETOL, NUEDEXTA, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, VYJUVEK, Veozah, Wegovy, XHANCE, XIFAXAN, ZAVZPRET, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error